P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL-102)

M. Hamadani, M. Coleman, R. Boccia, J. Duras, M. Hutchings, P. L. Zinzani, R. Cordoba, M. B. Oreiro, V. Williams, M. Stouffs, P. Langmuir, J.-M. Sancho

Open source

DOI
10.1097/01.hs9.0000847284.03476.7b
Published
2022-06
Container
HemaSphere
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1097/01.hs9.0000847284.03476.7b,
  title = {P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL-102)},
  author = {M. Hamadani and M. Coleman and R. Boccia and J. Duras and M. Hutchings and P. L. Zinzani and R. Cordoba and M. B. Oreiro and V. Williams and M. Stouffs and P. Langmuir and J.-M. Sancho},
  year = {2022},
  journal = {HemaSphere},
  doi = {10.1097/01.hs9.0000847284.03476.7b},
  url = {https://doi.org/10.1097/01.hs9.0000847284.03476.7b}
}

RIS

TY  - JOUR
TI  - P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL-102)
AU  - M. Hamadani
AU  - M. Coleman
AU  - R. Boccia
AU  - J. Duras
AU  - M. Hutchings
AU  - P. L. Zinzani
AU  - R. Cordoba
AU  - M. B. Oreiro
AU  - V. Williams
AU  - M. Stouffs
AU  - P. Langmuir
AU  - J.-M. Sancho
PY  - 2022
JO  - HemaSphere
DO  - 10.1097/01.hs9.0000847284.03476.7b
UR  - https://doi.org/10.1097/01.hs9.0000847284.03476.7b
ER  - 

APA

Hamadani, M., Coleman, M., Boccia, R., Duras, J., Hutchings, M., Zinzani, P. L., Cordoba, R., Oreiro, M. B., Williams, V., Stouffs, M., Langmuir, P., & Sancho, J. (2022). P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL-102). HemaSphere. https://doi.org/10.1097/01.hs9.0000847284.03476.7b

Source records